Signed LOI with investor regarding investment in WATGEN MEDICAL A/S
31 oktober, 2019
Company Announcement No. 18
Vejle, October 31th, 2019
In company announcement no. 10, an expectation was communicated of a PRE-IPO capital increase of 10 MDKK to WATGEN MEDICAL A/S at a valuation of 65 MDKK before new capital.
Waturu Holding A/S owns 87,5% of WATGEN MEDICAL A/S. Belair Medical ApS owns 10% and the company is owned by co-founder Professor, MD, Dr.Sci., Peter Bjerring. Huidzaken Holding ApS owns 2,5% and the company is owned by CEO Jesper Nørregaard, WATGEN MEDICAL A/S.
A Letter of Intent (investment agreement) has been signed with an investor who will provide WATGEN MEDICAL A/S +10 MDKK in PRE-IPO and IPO capital. The investment will include a PRE-IPO valuation of 65 MDKK before new capital.
The agreement also include that the investor will participate in an upcoming IPO of WATGEN MEDICAL A/S, with an expected minimum value before new capital of +250 MDKK.
"It is an important step in our journey toward delivering new and improved technology to battle Atopic Dermatitis and secure better wound care for the patients with chronic wounds" - says CEO Jesper Nørregaard, WATGEN MEDICAL A/S
The interest in participating as a PRE-IPO investor has been incredibly and the management would like to take this opportunity to thank the many investors who have approached us.
After entering into a definitive investment agreement, the value impact of Waturu Holding A/S will be significant because of an expected significant value increase in WATGEN MEDICAL A/S within 1-2 years.
Following the conclusion of a definitive investment agreement, the management will announce the operational impact of Waturu Holding A/S.
Statement from CEO Toke Reedtz:
“Waturu technology has proven to create value in a wide variety of industries and contexts. As the company cannot be an expert in all these many different domains, the approach is, to separate dedicated companies focusing on the specific industry or business area, and in this context, provide the new company with the right skills and necessary capital to be able to focus on these promising business opportunities. In these contexts, it will primarily be capital from investors with in-depth knowledge of the specific business area. ”
More information:
CEO Toke Reedtz, tel: +45 5188 1262, e-mail: toke@waturu.com
CFO Michael Nørgaard, tel: +45 2720 6214, e-mail: mn@waturu.com
Waturu Holding A/S
Sjællandsgade 32
7100 Vejle
www.waturu.com
Certified Adviser:
Västra Hammen Corporate Finance AB
Per Lönn,
Jungmansgatan 12
211 11 Malmö Sweden
www.vhcorp.se
Nasdaq First North Growth Market Important links.:
Website: www.waturu.com
Financial reports: https://www.waturu.com/documents
Company Linkedin profile: https://www.linkedin.com/company/waturu
Company Facebook profile: https://www.facebook.com/WaturuDenmark/
Ämnen i artikeln
Signed LOI with investor regarding investment in WATGEN MEDICAL A/S
31 oktober, 2019
Company Announcement No. 18
Vejle, October 31th, 2019
In company announcement no. 10, an expectation was communicated of a PRE-IPO capital increase of 10 MDKK to WATGEN MEDICAL A/S at a valuation of 65 MDKK before new capital.
Waturu Holding A/S owns 87,5% of WATGEN MEDICAL A/S. Belair Medical ApS owns 10% and the company is owned by co-founder Professor, MD, Dr.Sci., Peter Bjerring. Huidzaken Holding ApS owns 2,5% and the company is owned by CEO Jesper Nørregaard, WATGEN MEDICAL A/S.
A Letter of Intent (investment agreement) has been signed with an investor who will provide WATGEN MEDICAL A/S +10 MDKK in PRE-IPO and IPO capital. The investment will include a PRE-IPO valuation of 65 MDKK before new capital.
The agreement also include that the investor will participate in an upcoming IPO of WATGEN MEDICAL A/S, with an expected minimum value before new capital of +250 MDKK.
"It is an important step in our journey toward delivering new and improved technology to battle Atopic Dermatitis and secure better wound care for the patients with chronic wounds" - says CEO Jesper Nørregaard, WATGEN MEDICAL A/S
The interest in participating as a PRE-IPO investor has been incredibly and the management would like to take this opportunity to thank the many investors who have approached us.
After entering into a definitive investment agreement, the value impact of Waturu Holding A/S will be significant because of an expected significant value increase in WATGEN MEDICAL A/S within 1-2 years.
Following the conclusion of a definitive investment agreement, the management will announce the operational impact of Waturu Holding A/S.
Statement from CEO Toke Reedtz:
“Waturu technology has proven to create value in a wide variety of industries and contexts. As the company cannot be an expert in all these many different domains, the approach is, to separate dedicated companies focusing on the specific industry or business area, and in this context, provide the new company with the right skills and necessary capital to be able to focus on these promising business opportunities. In these contexts, it will primarily be capital from investors with in-depth knowledge of the specific business area. ”
More information:
CEO Toke Reedtz, tel: +45 5188 1262, e-mail: toke@waturu.com
CFO Michael Nørgaard, tel: +45 2720 6214, e-mail: mn@waturu.com
Waturu Holding A/S
Sjællandsgade 32
7100 Vejle
www.waturu.com
Certified Adviser:
Västra Hammen Corporate Finance AB
Per Lönn,
Jungmansgatan 12
211 11 Malmö Sweden
www.vhcorp.se
Nasdaq First North Growth Market Important links.:
Website: www.waturu.com
Financial reports: https://www.waturu.com/documents
Company Linkedin profile: https://www.linkedin.com/company/waturu
Company Facebook profile: https://www.facebook.com/WaturuDenmark/
Ämnen i artikeln
Analyser
Rapportperioden
-992x558.jpg&w=3840&q=75)
Investor
Fonder
Bostadsmarknaden
Analyser
Rapportperioden
Mest läst
Investor
Fonder
Bostadsmarknaden
Senaste nytt
Marknadsöversikt
OMX Stockholm 30
1 DAG %
0,27%
Senast
2 398,84
1 mån
Loading market data...
Privatekonomi med Placeras expert
AFV
Igår, 16:32
